Meril designs, manufactures, and distributes clinically relevant medical devices focused on patient-centric healthcare solutions. The company offers a wide range of accessible medtech products, including advanced diagnostic assays for infectious diseases and self-testing kits. Meril maintains a strong commitment to R&D and high-quality manufacturing to advance global healthcare outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Healthcare providers and patients often lack rapid, reliable, and easy-to-use diagnostic tools for infectious diseases and other health conditions, especially in low-resource settings or at home. Conventional laboratory testing can be time‑consuming, require specialized equipment, and may not be accessible to all populations.
Solution
Meril designs, manufactures, and distributes a portfolio of clinically validated point‑of‑care diagnostic devices and self‑testing kits that deliver accurate results within minutes. The product line includes immunochromatographic assays for hepatitis B surface antigen, hepatitis C antibodies, HIV‑1/2 antibodies, malaria antigens, dengue, and COVID‑19 antigen, as well as home-use tests for early pregnancy, ovulation, and multi‑drug screening. Each test is provided in a ready‑to‑use cassette or kit format, requiring minimal sample preparation and no laboratory infrastructure. The assays meet high sensitivity and specificity standards (e.g., 99% accuracy for the pregnancy test) and are manufactured under strict quality controls to ensure consistent performance across global markets. Meril’s extensive distribution network spans over 100 countries, enabling rapid delivery to central labs, hospitals, pharmacies, and end‑users. Ongoing R&D investments support continuous improvement and expansion of the diagnostic portfolio to address emerging health threats.
Target Audience
Primary customers include clinical laboratories, hospitals, primary care physicians, pharmacists, and community health programs that require rapid point‑of‑care testing, as well as individual consumers seeking reliable home‑based self‑tests for infectious diseases and reproductive health monitoring.
Features
- Immunochromatographic rapid test cassettes for HBV, HCV, HIV‑1/2, malaria (Pf/Pv Ag & Pf/PAN Ag), dengue, and COVID‑19 antigen with results in 15‑20 minutes
- Self‑testing kits for HIV‑1/2 antibodies (blood and oral fluid), early pregnancy, ovulation, and multi‑drug detection, designed for home use without specialized equipment
- High analytical sensitivity and specificity (e.g., 99 % accuracy for early pregnancy test) validated through clinical studies
- Ready‑to‑use format with integrated sample collection, buffer, and result readout, minimizing user error
- Manufacturing compliant with international quality standards (ISO, CE, WHO pre‑qualification) and robust batch‑to‑batch consistency
- Global supply chain supporting distribution to >9,000 customers and 2,600+ channel partners across 145+ countries
- Continuous R&D pipeline delivering new assay formats and expanding disease coverage based on epidemiological trends